Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.

Aikawa N, Takahashi T, Fujimi S, Yokoyama T, Yoshihara K, Ikeda T, Sadamitsu D, Momozawa M, Maruyama T.

J Infect Chemother. 2013 Oct;19(5):931-40. doi: 10.1007/s10156-013-0612-y. Epub 2013 May 17.

PMID:
23681364
[PubMed - indexed for MEDLINE]
2.

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.

Morris PE, Zeno B, Bernard AC, Huang X, Das S, Edeki T, Simonson SG, Bernard GR.

Crit Care. 2012 Feb 17;16(1):R31. doi: 10.1186/cc11203.

PMID:
22340283
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.

Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, Larosa SP, Laterre PF, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X.

Crit Care Med. 2014 Mar;42(3):504-11. doi: 10.1097/CCM.0000000000000043.

PMID:
24335445
[PubMed - indexed for MEDLINE]
4.

Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis.

Yates JW, Das S, Mainwaring G, Kemp J.

J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):591-9. doi: 10.1007/s10928-012-9270-4. Epub 2012 Sep 23.

PMID:
23001587
[PubMed - indexed for MEDLINE]
5.

Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.

Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR.

Crit Care Med. 2006 Sep;34(9):2271-81.

PMID:
16810105
[PubMed - indexed for MEDLINE]
6.

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group.

Crit Care Med. 2001 Mar;29(3):503-10.

PMID:
11373411
[PubMed - indexed for MEDLINE]
7.

Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.

Newham P, Ross D, Ceuppens P, Das S, Yates JW, Betts C, Reens J, Randall KJ, Knight R, McKay JS.

Inflamm Res. 2014 Feb;63(2):149-60. doi: 10.1007/s00011-013-0683-3. Epub 2013 Nov 17.

PMID:
24240228
[PubMed - indexed for MEDLINE]
8.

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A.

JAMA. 1997 May 21;277(19):1531-8.

PMID:
9153367
[PubMed - indexed for MEDLINE]
9.

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J.

Crit Care Med. 1996 May;24(5):733-42. Erratum in: Crit Care Med 1996 Sep;24(9):1608.

PMID:
8706447
[PubMed - indexed for MEDLINE]
10.

The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ.

Expert Opin Investig Drugs. 2011 Nov;20(11):1555-64. doi: 10.1517/13543784.2011.623125. Epub 2011 Oct 1. Review.

PMID:
21961576
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.

Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schüttler J, Gärtner R.

Crit Care Med. 2007 Jan;35(1):118-26.

PMID:
17095947
[PubMed - indexed for MEDLINE]
12.

CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.

Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M.

Crit Care Med. 1995 Sep;23(9):1461-9.

PMID:
7664546
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al.

JAMA. 1995 Mar 22-29;273(12):934-41.

PMID:
7884952
[PubMed - indexed for MEDLINE]
14.

Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.

Butty VL, Roux-Lombard P, Garbino J, Dayer JM, Ricou B; Geneva Sepsis Network.

Eur Cytokine Netw. 2003 Jan-Mar;14(1):15-9.

PMID:
12799209
[PubMed - indexed for MEDLINE]
16.

Does N-acetyl-L-cysteine influence cytokine response during early human septic shock?

Spapen H, Zhang H, Demanet C, Vleminckx W, Vincent JL, Huyghens L.

Chest. 1998 Jun;113(6):1616-24.

PMID:
9631802
[PubMed - indexed for MEDLINE]
17.

Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock.

Mussack T, Briegel J, Schelling G, Biberthaler P, Jochum M.

Clin Chem Lab Med. 2005;43(3):259-68.

PMID:
15843228
[PubMed - indexed for MEDLINE]
18.

Randomized controlled trial of calcitriol in severe sepsis.

Leaf DE, Raed A, Donnino MW, Ginde AA, Waikar SS.

Am J Respir Crit Care Med. 2014 Sep 1;190(5):533-41. doi: 10.1164/rccm.201405-0988OC.

PMID:
25029202
[PubMed - indexed for MEDLINE]
19.

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA; IL-1RA Sepsis Syndrome Study Group.

Crit Care Med. 1994 Jan;22(1):12-21.

PMID:
8124953
[PubMed - indexed for MEDLINE]
20.

Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.

Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K.

Crit Care Med. 1999 Apr;27(4):723-32.

PMID:
10321661
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk